{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-013637","form_type":"8-K","ticker":"BBOT","cik":"0001869105","company_name":"BridgeBio Oncology Therapeutics, Inc.","filed_at":"2024-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.169961+00:00","generated_at":"2026-06-06T02:40:17.270006+00:00","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Helix Acquisition Corp. II closes $184M IPO, including full over-allotment","bullets":["Closed IPO of 18.4M Class A shares at $10.00 each; gross proceeds $184M.","Underwriter exercised over-allotment option in full for additional 2.4M shares.","Sponsor purchased 509,000 private placement shares at $10.00 for $5.09M.","Total $184M placed in trust; must complete business combination within 24 months.","Appointed Mark C. McKenna and John Schmid as independent directors; charter amended."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-013637","json":"https://secwatch.observer/filing/0001213900-24-013637.json","markdown":"https://secwatch.observer/filing/0001213900-24-013637.md","text":"https://secwatch.observer/filing/0001213900-24-013637.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1869105/000121390024013637/0001213900-24-013637-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1869105/000121390024013637/ea193423-8k_helixacq2.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T02:40:17.270006+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"663fa67cdb","claim":"John Schmid was appointed as Director at BridgeBio Oncology Therapeutics, Inc..","evidence_excerpt":"Mr. Mark C. McKenna and Mr. John Schmid (the “ Directors ”) were appointed to the board of directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390024013637/0001213900-24-013637-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"9435f0c474","claim":"Mark C. McKenna was appointed as Director at BridgeBio Oncology Therapeutics, Inc..","evidence_excerpt":"Mr. Mark C. McKenna and Mr. John Schmid (the “ Directors ”) were appointed to the board of directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390024013637/0001213900-24-013637-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d09860280428380f3c9a5d25d786281f7eb9cf27","claim":"BridgeBio Oncology Therapeutics, Inc.: Amended and restated memorandum and articles of association filed and became effective in connection with IPO (effective 2024-02-08).","evidence_excerpt":"On February 8, 2024, in connection with the IPO, the Company filed its amended and restated memorandum and articles of association (the “ Amended Charter ”) with the Cayman Islands General Registry, effective the same day.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390024013637/0001213900-24-013637-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-02-08"}],"fact_type":"governance_change"},{"claim_id":"12df5a3aa08365af17b927643cfe1242461fa64e","claim":"BridgeBio Oncology Therapeutics, Inc. entered into Underwriting Agreement with Leerink Partners LLC (effective 2024-02-08).","evidence_excerpt":"n January 18, 2024 (as amended, the “ Registration Statement ”): ● An Underwriting Agreement, dated February 8, 2024, between the Company and Leerink Partners LLC, a copy of which is attached as Exhibit 1.1 hereto and incorporated herein by reference.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390024013637/0001213900-24-013637-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Leerink Partners LLC"},{"label":"Effective","value":"2024-02-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}